<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Praluent® (alirocumab) - Comprehensive Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            min-height: 100vh;
            padding: 20px;
        }

        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }

        .header {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }

        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 50%;
            height: 200%;
            background: rgba(255,255,255,0.1);
            transform: rotate(35deg);
        }

        .drug-title {
            position: relative;
            z-index: 1;
        }

        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
        }

        .drug-subtitle {
            font-size: 24px;
            opacity: 0.9;
            margin-bottom: 5px;
        }

        .drug-company {
            font-size: 18px;
            opacity: 0.8;
        }

        .badge-first {
            display: inline-block;
            background: rgba(255,255,255,0.3);
            padding: 5px 15px;
            border-radius: 20px;
            margin-top: 10px;
            font-size: 14px;
            font-weight: 600;
        }

        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e9ecef;
            padding: 0;
            overflow-x: auto;
        }

        .nav-tab {
            padding: 20px 30px;
            cursor: pointer;
            border: none;
            background: none;
            font-size: 16px;
            font-weight: 500;
            color: #6c757d;
            transition: all 0.3s;
            white-space: nowrap;
            position: relative;
        }

        .nav-tab:hover {
            color: #f5576c;
            background: rgba(245, 87, 108, 0.05);
        }

        .nav-tab.active {
            color: #f5576c;
            background: white;
        }

        .nav-tab.active::after {
            content: '';
            position: absolute;
            bottom: -2px;
            left: 0;
            right: 0;
            height: 3px;
            background: linear-gradient(90deg, #f093fb 0%, #f5576c 100%);
        }

        .content {
            padding: 40px;
        }

        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }

        .tab-content.active {
            display: block;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .section {
            margin-bottom: 40px;
        }

        .section-title {
            font-size: 28px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 3px solid #f5576c;
        }

        .mechanism-card {
            background: linear-gradient(135deg, #ffeaa7 0%, #fdcb6e 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }

        .mechanism-title {
            font-size: 22px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 15px;
        }

        .mechanism-content {
            color: #5a6c7d;
            line-height: 1.8;
            font-size: 16px;
        }

        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .dosing-card {
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }

        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(245, 87, 108, 0.2);
            border-color: #f5576c;
        }

        .dosing-label {
            font-size: 14px;
            color: #6c757d;
            margin-bottom: 10px;
        }

        .dosing-value {
            font-size: 28px;
            font-weight: bold;
            color: #f5576c;
            margin-bottom: 10px;
        }

        .dosing-detail {
            font-size: 14px;
            color: #5a6c7d;
        }

        .dosing-special {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
        }

        .dosing-special .dosing-label,
        .dosing-special .dosing-detail {
            color: rgba(255,255,255,0.9);
        }

        .dosing-special .dosing-value {
            color: white;
        }

        .timeline-container {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }

        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #f093fb 0%, #f5576c 100%);
            transform: translateX(-50%);
        }

        .timeline-item {
            position: relative;
            margin: 30px 0;
            display: flex;
            align-items: center;
        }

        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }

        .timeline-content {
            width: 45%;
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            transition: all 0.3s;
            cursor: pointer;
        }

        .timeline-content:hover {
            transform: scale(1.05);
            box-shadow: 0 10px 30px rgba(245, 87, 108, 0.3);
            border-color: #f5576c;
        }

        .timeline-date {
            font-size: 18px;
            font-weight: bold;
            color: #f5576c;
            margin-bottom: 10px;
        }

        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            color: #2c3e50;
            margin-bottom: 8px;
        }

        .timeline-description {
            font-size: 14px;
            color: #6c757d;
            line-height: 1.6;
        }

        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: white;
            border: 4px solid #f5576c;
            border-radius: 50%;
            z-index: 2;
        }

        .timeline-highlight {
            background: #fff3cd !important;
            border-color: #ffc107 !important;
        }

        .timeline-highlight .timeline-date {
            color: #d39e00;
        }

        .trials-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin-top: 20px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            border-radius: 12px;
            overflow: hidden;
        }

        .trials-table thead {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
        }

        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
            font-size: 14px;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .trials-table tbody tr {
            border-bottom: 1px solid #e9ecef;
            transition: all 0.3s;
        }

        .trials-table tbody tr:hover {
            background: rgba(245, 87, 108, 0.05);
            transform: translateX(5px);
        }

        .trials-table td {
            padding: 15px;
            font-size: 14px;
            color: #5a6c7d;
        }

        .trial-name {
            font-weight: 600;
            color: #2c3e50;
        }

        .trial-phase {
            display: inline-block;
            padding: 4px 8px;
            border-radius: 4px;
            font-size: 12px;
            font-weight: 600;
            background: #e9ecef;
            color: #6c757d;
        }

        .trial-phase.phase3 {
            background: #d4edda;
            color: #155724;
        }

        .landmark-trial {
            background: rgba(245, 87, 108, 0.05) !important;
        }

        .landmark-trial .trial-name {
            color: #f5576c;
            font-weight: bold;
        }

        .efficacy-bar-chart {
            display: flex;
            align-items: flex-end;
            justify-content: space-around;
            height: 300px;
            padding: 20px;
            background: white;
            border-radius: 12px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }

        .bar-group {
            flex: 1;
            display: flex;
            flex-direction: column;
            align-items: center;
            margin: 0 10px;
        }

        .bar {
            width: 60px;
            background: linear-gradient(180deg, #f093fb 0%, #f5576c 100%);
            border-radius: 8px 8px 0 0;
            transition: all 0.3s;
            position: relative;
            margin-bottom: 10px;
        }

        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(245, 87, 108, 0.4);
        }

        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            color: #f5576c;
            font-size: 18px;
        }

        .bar-label {
            text-align: center;
            font-size: 12px;
            color: #6c757d;
            margin-top: 10px;
            max-width: 100px;
        }

        .mortality-highlight {
            background: linear-gradient(135deg, #74b9ff 0%, #0984e3 100%) !important;
        }

        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .safety-card {
            background: white;
            border: 1px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            transition: all 0.3s;
        }

        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }

        .safety-title {
            font-size: 18px;
            font-weight: 600;
            color: #2c3e50;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }

        .safety-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            border-radius: 50%;
            margin-right: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-weight: bold;
        }

        .safety-content {
            color: #6c757d;
            line-height: 1.8;
        }

        .safety-list {
            list-style: none;
            margin-top: 10px;
        }

        .safety-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f1f3f5;
            display: flex;
            justify-content: space-between;
        }

        .safety-list li:last-child {
            border-bottom: none;
        }

        .percentage {
            font-weight: 600;
            color: #f5576c;
        }

        .market-timeline {
            position: relative;
            padding: 30px 0;
        }

        .market-event {
            background: white;
            border-left: 4px solid #f5576c;
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 12px 12px 0;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            transition: all 0.3s;
        }

        .market-event:hover {
            transform: translateX(10px);
            box-shadow: 0 10px 30px rgba(245, 87, 108, 0.2);
        }

        .market-year {
            font-size: 20px;
            font-weight: bold;
            color: #f5576c;
            margin-bottom: 10px;
        }

        .market-description {
            color: #5a6c7d;
            line-height: 1.6;
        }

        .price-tag {
            display: inline-block;
            background: #ffeaa7;
            color: #2d3436;
            padding: 5px 10px;
            border-radius: 5px;
            font-weight: 600;
            margin: 5px 0;
        }

        .value-tag {
            display: inline-block;
            background: #74b9ff;
            color: white;
            padding: 5px 10px;
            border-radius: 5px;
            font-weight: 600;
            margin: 5px 0;
        }

        .competition-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }

        .competitor-card {
            background: white;
            border: 2px solid #e9ecef;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }

        .competitor-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
            border-color: #f5576c;
        }

        .competitor-name {
            font-size: 18px;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 10px;
        }

        .competitor-detail {
            font-size: 14px;
            color: #6c757d;
            margin: 5px 0;
        }

        .comparison-table {
            width: 100%;
            margin-top: 20px;
            border-collapse: separate;
            border-spacing: 0;
            border-radius: 12px;
            overflow: hidden;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }

        .comparison-table thead {
            background: linear-gradient(135deg, #74b9ff 0%, #0984e3 100%);
            color: white;
        }

        .comparison-table th,
        .comparison-table td {
            padding: 15px;
            text-align: left;
        }

        .comparison-table tbody tr {
            border-bottom: 1px solid #e9ecef;
        }

        .comparison-table tbody tr:hover {
            background: rgba(116, 185, 255, 0.05);
        }

        .feature-name {
            font-weight: 600;
            color: #2c3e50;
        }

        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 10px auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">Praluent® (alirocumab)</div>
                <div class="drug-subtitle">PCSK9 Monoclonal Antibody</div>
                <div class="drug-company">Sanofi/Regeneron • FDA/EMA Approved 2015</div>
                <div class="badge-first">FIRST PCSK9 INHIBITOR APPROVED IN US</div>
            </div>
        </div>

        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('market')">Market & Commercial</button>
            <button class="nav-tab" onclick="showTab('comparison')">vs. Repatha</button>
        </div>

        <div class="content">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="section">
                    <h2 class="section-title">Mechanism of Action</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">PCSK9 Inhibition via Monoclonal Antibody</div>
                        <div class="mechanism-content">
                            Praluent is a fully human monoclonal antibody with high affinity binding to circulating PCSK9, preventing its interaction with LDL receptors on hepatocytes. This mechanism leads to:
                            <ul style="margin-top: 15px; margin-left: 20px;">
                                <li style="margin: 8px 0;">Prevention of PCSK9-mediated LDL-R degradation</li>
                                <li style="margin: 8px 0;">Increased LDL-R density on liver cell surface</li>
                                <li style="margin: 8px 0;">Enhanced uptake and catabolism of LDL-C</li>
                                <li style="margin: 8px 0;">Substantial serum LDL-C reductions (50-60%)</li>
                                <li style="margin: 8px 0;">Rapid onset within days, peak effect by 4-8 weeks</li>
                            </ul>
                            <div style="margin-top: 20px; padding: 15px; background: rgba(245, 87, 108, 0.1); border-radius: 8px;">
                                <strong>Key Differentiators:</strong> Acts extracellularly in plasma with rapid onset compared to inclisiran's delayed gene-silencing mechanism. Equivalent to evolocumab in PCSK9 inhibition potency but offers lower starting dose for titration flexibility.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Dosing & Administration</h2>
                    <div class="dosing-grid">
                        <div class="dosing-card dosing-special">
                            <div class="dosing-label">Unique Starting Dose</div>
                            <div class="dosing-value">75 mg</div>
                            <div class="dosing-detail">Every 2 weeks (Q2W)<br>Lower than competitors</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Titrated Dose</div>
                            <div class="dosing-value">150 mg</div>
                            <div class="dosing-detail">Q2W if LDL-C target not met<br>(e.g., <70 mg/dL)</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Alternative Regimen</div>
                            <div class="dosing-value">300 mg</div>
                            <div class="dosing-detail">Every 4 weeks (Q4W)<br>Two 150 mg injections</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Annual Injections</div>
                            <div class="dosing-value">12-26</div>
                            <div class="dosing-detail">More than inclisiran (2-3)<br>Less than daily orals</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">HoFH Dosing</div>
                            <div class="dosing-value">150 mg</div>
                            <div class="dosing-detail">Q2W maximum<br>Lower efficacy due to LDL-R dependency</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Pediatric (8+)</div>
                            <div class="dosing-value">Weight-based</div>
                            <div class="dosing-detail">HeFH/HoFH patients<br>FDA approved 2024</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Patient Populations</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Approved Indications</div>
                        <div class="mechanism-content">
                            <strong>Adults:</strong>
                            <ul style="margin: 10px 0 10px 20px;">
                                <li>Heterozygous Familial Hypercholesterolemia (HeFH)</li>
                                <li>Homozygous Familial Hypercholesterolemia (HoFH) - added 2021</li>
                                <li>Clinical ASCVD requiring additional LDL-C lowering</li>
                                <li>CV risk reduction (MI, stroke, unstable angina) - added 2019</li>
                                <li>Statin-intolerant patients (EMA broader indication)</li>
                            </ul>
                            <strong>Pediatric (Age 8+):</strong>
                            <ul style="margin: 10px 0 10px 20px;">
                                <li>HeFH or HoFH patients (FDA 2024, EMA 2023)</li>
                                <li>Weight-based dosing considerations</li>
                            </ul>
                            <div style="margin-top: 15px; padding: 10px; background: #d4edda; border-radius: 5px;">
                                <strong>Advantage:</strong> Lower starting dose (75 mg) allows for better tolerability and titration flexibility compared to fixed-dose competitors
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="section">
                    <h2 class="section-title">FDA Approval Timeline</h2>
                    <div class="timeline-container">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content timeline-highlight">
                                <div class="timeline-date">July 24, 2015</div>
                                <div class="timeline-title">Initial FDA Approval - FIRST PCSK9i</div>
                                <div class="timeline-description">
                                    First PCSK9 inhibitor approved in US. For HeFH and clinical ASCVD as adjunct to diet/statins.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">April 26, 2019</div>
                                <div class="timeline-title">CV Outcomes Indication</div>
                                <div class="timeline-description">
                                    Label expansion for MI, stroke, and unstable angina reduction based on ODYSSEY OUTCOMES trial showing mortality benefit.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">April 1, 2021</div>
                                <div class="timeline-title">HoFH Indication</div>
                                <div class="timeline-description">
                                    Expanded to adults with homozygous familial hypercholesterolemia as adjunct to other therapies.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 11, 2024</div>
                                <div class="timeline-title">Pediatric Expansion</div>
                                <div class="timeline-description">
                                    Age limit lowered to 8+ years for HeFH patients, younger than competitor approvals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2025</div>
                                <div class="timeline-title">Latest Updates</div>
                                <div class="timeline-description">
                                    Updated pregnancy/lactation data from registries. No fetal harm signals but discontinuation advised. No new restrictions.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>

                    <h2 class="section-title">EMA Approval Timeline</h2>
                    <div class="timeline-container">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">September 23, 2015</div>
                                <div class="timeline-title">EMA Marketing Authorization</div>
                                <div class="timeline-description">
                                    Broader initial indication than FDA, including statin-intolerant patients. For primary hypercholesterolemia and mixed dyslipidemia.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 15, 2019</div>
                                <div class="timeline-title">CV Risk Reduction</div>
                                <div class="timeline-description">
                                    Expanded for CV risk reduction in adults with established atherosclerotic CVD.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2021</div>
                                <div class="timeline-title">HoFH Addition</div>
                                <div class="timeline-description">
                                    Added indication for homozygous familial hypercholesterolemia in adults.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2023-2024</div>
                                <div class="timeline-title">Pediatric Extension</div>
                                <div class="timeline-description">
                                    Extended to ages 8+ for HeFH/HoFH. Continuous PBRERs show no new safety signals.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>

                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">October 2023</div>
                                <div class="timeline-title">Latest Revision</div>
                                <div class="timeline-description">
                                    2025 confirmations via variation reports. No withdrawals, though pricing negotiations ongoing in France.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <div class="section">
                    <h2 class="section-title">ODYSSEY Clinical Development Program</h2>
                    
                    <table class="trials-table">
                        <thead>
                            <tr>
                                <th>Trial Name</th>
                                <th>Phase</th>
                                <th>N</th>
                                <th>Year</th>
                                <th>Primary Endpoint</th>
                                <th>Key Results</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="trial-name">DF490336</td>
                                <td><span class="trial-phase">Phase 1</span></td>
                                <td>183</td>
                                <td>2013</td>
                                <td>PK/PD</td>
                                <td>LDL-C reductions up to 72%</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY MONO</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>103</td>
                                <td>2014</td>
                                <td>% LDL-C change at week 24</td>
                                <td>47% reduction vs ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY COMBO I/II</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>1,036</td>
                                <td>2014</td>
                                <td>% LDL-C change at week 24</td>
                                <td>48-50% reduction with statins</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY FH I/II</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>735</td>
                                <td>2015</td>
                                <td>% LDL-C change at week 24 (HeFH)</td>
                                <td>~58% reduction in HeFH</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY OPTIONS I/II</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>650</td>
                                <td>2015</td>
                                <td>% LDL-C change vs alternatives</td>
                                <td>Superior to doubling statin/adding ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY ALTERNATIVE</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>314</td>
                                <td>2015</td>
                                <td>% LDL-C (statin-intolerant)</td>
                                <td>45% reduction vs ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY LONG TERM</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>2,341</td>
                                <td>2015</td>
                                <td>% LDL-C change at week 24</td>
                                <td>61% reduction; exploratory MACE HR 0.52</td>
                            </tr>
                            <tr class="landmark-trial">
                                <td class="trial-name"><strong>ODYSSEY OUTCOMES</strong></td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td><strong>18,924</strong></td>
                                <td><strong>2018</strong></td>
                                <td><strong>MACE (CV death, MI, stroke, UA)</strong></td>
                                <td><strong>HR 0.85 (15% RRR); Mortality HR 0.85 (p=0.026)</strong></td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY CHOICE I/II</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>1,158</td>
                                <td>2016</td>
                                <td>% LDL-C change (Q4W dosing)</td>
                                <td>52-59% reduction, Q4W confirmed</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY EAST</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>615</td>
                                <td>2019</td>
                                <td>% LDL-C change (Asian)</td>
                                <td>56% reduction vs ezetimibe</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY HoFH</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>69</td>
                                <td>2020</td>
                                <td>% LDL-C change (HoFH)</td>
                                <td>36% reduction</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY OUTCOMES OLE</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>8,242</td>
                                <td>2023</td>
                                <td>Long-term MACE (up to 6 years)</td>
                                <td>Sustained MACE reduction, low AEs</td>
                            </tr>
                            <tr>
                                <td class="trial-name">ODYSSEY KIDS</td>
                                <td><span class="trial-phase phase3">Phase 3</span></td>
                                <td>42</td>
                                <td>2024</td>
                                <td>% LDL-C change (pediatric)</td>
                                <td>35-46% reduction</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="section">
                    <h2 class="section-title">Efficacy Outcomes</h2>
                    <div class="efficacy-bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 55%;">
                                <span class="bar-value">55%</span>
                            </div>
                            <div class="bar-label">LDL-C Reduction<br>(ODYSSEY OUTCOMES)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 61%; background: linear-gradient(180deg, #48dbfb 0%, #0984e3 100%);">
                                <span class="bar-value">61%</span>
                            </div>
                            <div class="bar-label">LDL-C Reduction<br>(LONG TERM)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 53%; background: linear-gradient(180deg, #fdcb6e 0%, #e17055 100%);">
                                <span class="bar-value">53 mg/dL</span>
                            </div>
                            <div class="bar-label">Median LDL<br>Achieved</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar mortality-highlight" style="height: 15%;">
                                <span class="bar-value" style="color: #0984e3;">15%</span>
                            </div>
                            <div class="bar-label">All-Cause Mortality<br>Reduction (p=0.026)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 15%; background: linear-gradient(180deg, #a29bfe 0%, #6c5ce7 100%);">
                                <span class="bar-value">15%</span>
                            </div>
                            <div class="bar-label">MACE Reduction<br>(Overall)</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 24%; background: linear-gradient(180deg, #55efc4 0%, #00b894 100%);">
                                <span class="bar-value">24%</span>
                            </div>
                            <div class="bar-label">MACE Reduction<br>(LDL ≥100 mg/dL)</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">ODYSSEY OUTCOMES - Detailed Analysis</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Primary & Secondary Endpoints</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-top: 20px;">
                                <div>
                                    <strong>Primary Composite MACE:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>CV death, nonfatal MI/stroke, UA hospitalization</li>
                                        <li><strong>HR 0.85 (95% CI: 0.78-0.93)</strong></li>
                                        <li><strong>15% relative risk reduction, p<0.001</strong></li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>All-Cause Mortality (Key Finding):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li><strong>HR 0.85 (95% CI: 0.73-0.98)</strong></li>
                                        <li><strong>15% reduction (3.5% vs 4.1%)</strong></li>
                                        <li><strong>Nominal p=0.026</strong></li>
                                    </ul>
                                </div>
                            </div>
                            <div style="margin-top: 20px; padding: 15px; background: #d4edda; border-radius: 8px;">
                                <strong>Unique Finding:</strong> ODYSSEY OUTCOMES showed nominal mortality benefit not seen with evolocumab (FOURIER). Greatest benefit in patients with baseline LDL ≥100 mg/dL: MACE 24% RRR, death 29% RRR. Median follow-up 2.8 years.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Safety Profile Overview</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-content">
                            <strong>Cumulative Exposure:</strong> ~1.5-2 million patient-years by 2025<br>
                            <strong>Black Box Warnings:</strong> None<br>
                            <strong>Major Safety Signals:</strong> None identified<br>
                            <strong>Discontinuation Rate:</strong> ~2% due to adverse events<br>
                            <strong>Immunogenicity:</strong> Anti-drug antibodies ~5%, neutralizing <1%
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Common Adverse Events</h2>
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">1</div>
                                Most Common AEs
                            </div>
                            <div class="safety-content">
                                <ul class="safety-list">
                                    <li>Nasopharyngitis <span class="percentage">11.3%</span></li>
                                    <li>Injection site reactions <span class="percentage">7.2%</span></li>
                                    <li>Upper respiratory infection <span class="percentage">5.7%</span></li>
                                    <li>Influenza <span class="percentage">5.7%</span></li>
                                    <li>Myalgia <span class="percentage">5.4%</span></li>
                                    <li>UTI <span class="percentage">4.8%</span></li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">2</div>
                                Injection Site Reactions
                            </div>
                            <div class="safety-content">
                                Overall incidence: 7.2% (vs 5.1% placebo)
                                <ul class="safety-list">
                                    <li>Pruritus <span class="percentage">Most common</span></li>
                                    <li>Erythema <span class="percentage">Common</span></li>
                                    <li>Pain <span class="percentage">Less common</span></li>
                                </ul>
                                Higher than Repatha (5.7%) but generally mild
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">3</div>
                                Serious Adverse Events
                            </div>
                            <div class="safety-content">
                                <ul class="safety-list">
                                    <li>Overall SAEs <span class="percentage">4.8%</span></li>
                                    <li>Similar to placebo <span class="percentage">Yes</span></li>
                                    <li>Immunogenicity <span class="percentage">5% ADA</span></li>
                                    <li>Neutralizing antibodies <span class="percentage"><1%</span></li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Neurocognitive & Metabolic Safety</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Long-Term Safety Data</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div>
                                    <strong>Neurocognitive Effects:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Neurocognitive AEs: 1.2% vs 0.7% placebo</li>
                                        <li>No association with LDL <25 mg/dL</li>
                                        <li>2025 meta-analyses confirm no link</li>
                                        <li>Rare reports non-causal</li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>Metabolic Effects:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>New-onset diabetes: HR 1.18 (slight increase)</li>
                                        <li>Similar to statin effect</li>
                                        <li>Ophthalmologic AEs: 1.3% (same as placebo)</li>
                                        <li>No cataract increase</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: #fff3cd; border-radius: 8px;">
                                <strong>Real-World Evidence:</strong> 2025 data from Japan shows low AE rates consistent with trials. Benign profile in T1D patients. Similar to inclisiran but with more extensive long-term data.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Special Populations</h2>
                    <div class="safety-grid">
                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">P</div>
                                Pregnancy & Lactation
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>• No fetal harm signals in registries</li>
                                    <li>• Discontinuation advised during pregnancy</li>
                                    <li>• Limited lactation data</li>
                                    <li>• 2025 label update with registry data</li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">S</div>
                                Statin-Intolerant
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>• ODYSSEY ALTERNATIVE trial</li>
                                    <li>• 45% LDL-C reduction</li>
                                    <li>• Well-tolerated profile</li>
                                    <li>• EMA broader indication</li>
                                </ul>
                            </div>
                        </div>

                        <div class="safety-card">
                            <div class="safety-title">
                                <div class="safety-icon">K</div>
                                Pediatric (8+)
                            </div>
                            <div class="safety-content">
                                <ul style="list-style: none;">
                                    <li>• ODYSSEY KIDS trial</li>
                                    <li>• 35-46% LDL-C reduction</li>
                                    <li>• Similar safety to adults</li>
                                    <li>• Youngest approval age (8+)</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Market Tab -->
            <div id="market" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Pricing & Access Evolution</h2>
                    <div class="market-timeline">
                        <div class="market-event">
                            <div class="market-year">2015</div>
                            <div class="market-description">
                                <span class="price-tag">US: $14,000-14,600/year</span>
                                <span class="price-tag">EU: ~€5,000/year</span><br>
                                Launch as first PCSK9 inhibitor with high pricing leading to immediate payer pushback
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2018-2019</div>
                            <div class="market-description">
                                <span class="price-tag">60% price cut to $5,850/year</span><br>
                                Post-ODYSSEY OUTCOMES price reduction. Net ~$4,000 with rebates<br>
                                <span class="value-tag">Value-based contracts piloted</span>
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2019</div>
                            <div class="market-description">
                                Partnership restructure: Regeneron takes US rights, Sanofi maintains ex-US<br>
                                <span class="value-tag">Copay cards: $50/month for eligible</span>
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2025</div>
                            <div class="market-description">
                                <span class="price-tag">Annual sales: ~$400-500M</span><br>
                                Sales plateaued below Repatha. Competition from inclisiran and oral PCSK9i
                            </div>
                        </div>

                        <div class="market-event">
                            <div class="market-year">2027-2028</div>
                            <div class="market-description">
                                Patent expiry approaching. Biosimilars expected (Samsung Bioepis in pipeline)<br>
                                Projected 40-60% price reduction with biosimilar entry
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Market Access Innovations</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Value-Based Contracting</div>
                        <div class="mechanism-content">
                            <strong>Unique Market Approach:</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>First PCSK9i with value-based contracts (2018)</li>
                                <li>Refunds for CV events while on therapy</li>
                                <li>Copay assistance programs ($50/month)</li>
                                <li>OOP costs dropped 50% post-price cut</li>
                                <li>Medicare beneficiaries: $25-150/month</li>
                            </ul>
                            
                            <strong>Access Barriers (Similar to Repatha):</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>70-80% initial prior authorization denials</li>
                                <li>Requirements: statin intolerance/failure, high LDL (>100-130 mg/dL)</li>
                                <li>CV risk documentation needed</li>
                                <li>Uptake <5-10% of eligible patients</li>
                            </ul>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Competitive Landscape</h2>
                    <div class="competition-grid">
                        <div class="competitor-card">
                            <div class="competitor-name">Repatha (evolocumab)</div>
                            <div class="competitor-detail">PCSK9 mAb - Amgen</div>
                            <div class="competitor-detail">Higher sales, similar efficacy</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Leqvio (inclisiran)</div>
                            <div class="competitor-detail">siRNA - Novartis</div>
                            <div class="competitor-detail">Twice-yearly dosing</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Oral PCSK9i</div>
                            <div class="competitor-detail">Multiple in development</div>
                            <div class="competitor-detail">Daily oral convenience</div>
                        </div>
                        
                        <div class="competitor-card">
                            <div class="competitor-name">Biosimilars</div>
                            <div class="competitor-detail">Samsung Bioepis et al.</div>
                            <div class="competitor-detail">Expected 2028+</div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Future Outlook</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Market Evolution & Pipeline</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div>
                                    <strong>Near-Term (2025-2028):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Patent expiry US/EU ~2027-2028</li>
                                        <li>Limited lifecycle management</li>
                                        <li>Higher HoFH doses explored</li>
                                        <li>No new formulations planned</li>
                                    </ul>
                                </div>
                                <div>
                                    <strong>Long-Term (2028-2035):</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Biosimilars cut prices 40-60%</li>
                                        <li>Orals may dominate first-line</li>
                                        <li>Injections for non-adherent/acute</li>
                                        <li>Global biosimilar market $70B+</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: rgba(245, 87, 108, 0.1); border-radius: 8px;">
                                <strong>Legacy Position:</strong> Praluent pioneered PCSK9 inhibition as first FDA-approved agent. Mortality signal in ODYSSEY OUTCOMES remains unique differentiator. Focus shifting to Lp(a) inhibitors and next-generation lipid therapies.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Comparison Tab -->
            <div id="comparison" class="tab-content">
                <div class="section">
                    <h2 class="section-title">Praluent vs. Repatha Head-to-Head Comparison</h2>
                    
                    <table class="comparison-table">
                        <thead>
                            <tr>
                                <th>Feature</th>
                                <th>Praluent (alirocumab)</th>
                                <th>Repatha (evolocumab)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td class="feature-name">FDA Approval</td>
                                <td>July 24, 2015 (FIRST)</td>
                                <td>August 27, 2015</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Starting Dose</td>
                                <td>75 mg Q2W (titratable)</td>
                                <td>140 mg Q2W (fixed)</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Alternative Dosing</td>
                                <td>300 mg Q4W</td>
                                <td>420 mg monthly</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Pediatric Age</td>
                                <td>8+ years</td>
                                <td>10+ years</td>
                            </tr>
                            <tr>
                                <td class="feature-name">LDL-C Reduction</td>
                                <td>50-60%</td>
                                <td>50-70%</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Landmark Trial</td>
                                <td>ODYSSEY OUTCOMES (n=18,924)</td>
                                <td>FOURIER (n=27,564)</td>
                            </tr>
                            <tr>
                                <td class="feature-name">MACE Reduction</td>
                                <td>15% (HR 0.85)</td>
                                <td>15-20% (HR 0.85)</td>
                            </tr>
                            <tr style="background: rgba(116, 185, 255, 0.1);">
                                <td class="feature-name"><strong>Mortality Benefit</strong></td>
                                <td><strong>Yes (HR 0.85, p=0.026)</strong></td>
                                <td><strong>No (HR 1.04)</strong></td>
                            </tr>
                            <tr>
                                <td class="feature-name">ISR Rate</td>
                                <td>7.2%</td>
                                <td>5.7%</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Immunogenicity</td>
                                <td>5% ADA, <1% neutralizing</td>
                                <td>0.3% ADA, rare neutralizing</td>
                            </tr>
                            <tr>
                                <td class="feature-name">2025 Sales</td>
                                <td>~$400-500M</td>
                                <td>~$1.3B</td>
                            </tr>
                            <tr>
                                <td class="feature-name">List Price (2025)</td>
                                <td>$5,850/year</td>
                                <td>$5,850/year</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Patent Expiry</td>
                                <td>2027-2028</td>
                                <td>Late 2027</td>
                            </tr>
                            <tr>
                                <td class="feature-name">Key Advantage</td>
                                <td>Lower starting dose, mortality signal</td>
                                <td>Larger trial, lower ISR rate</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="section">
                    <h2 class="section-title">Clinical Positioning</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">When to Choose Each Agent</div>
                        <div class="mechanism-content">
                            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                                <div style="padding: 20px; background: rgba(245, 87, 108, 0.05); border-radius: 8px;">
                                    <strong>Consider Praluent When:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Lower starting dose desired for tolerability</li>
                                        <li>Titration flexibility needed</li>
                                        <li>Q4W dosing preferred (300 mg option)</li>
                                        <li>Younger pediatric patients (8+ vs 10+)</li>
                                        <li>Very high-risk patients (mortality benefit)</li>
                                    </ul>
                                </div>
                                <div style="padding: 20px; background: rgba(102, 126, 234, 0.05); border-radius: 8px;">
                                    <strong>Consider Repatha When:</strong>
                                    <ul style="margin: 10px 0 10px 20px;">
                                        <li>Fixed dosing simplicity preferred</li>
                                        <li>Lower injection site reaction risk important</li>
                                        <li>Extensive long-term safety data desired</li>
                                        <li>Monthly single-dose option needed</li>
                                        <li>Lower immunogenicity concerns</li>
                                    </ul>
                                </div>
                            </div>
                            
                            <div style="margin-top: 20px; padding: 15px; background: #d4edda; border-radius: 8px;">
                                <strong>Clinical Equivalence:</strong> Both agents are considered therapeutically equivalent for LDL-C reduction and CV risk reduction. Choice often based on formulary coverage, patient preference for dosing regimen, and individual tolerability. The mortality signal with Praluent may influence choice in highest-risk patients.
                            </div>
                        </div>
                    </div>
                </div>

                <div class="section">
                    <h2 class="section-title">Market Dynamics</h2>
                    <div class="mechanism-card">
                        <div class="mechanism-title">Commercial Performance Comparison</div>
                        <div class="mechanism-content">
                            <strong>Sales Performance Gap:</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>Repatha outsells Praluent ~3:1 despite similar efficacy</li>
                                <li>Amgen's stronger cardiovascular portfolio presence</li>
                                <li>Better payer relationships and formulary positioning</li>
                                <li>2019 partnership restructure impacted Praluent momentum</li>
                            </ul>
                            
                            <strong>Biosimilar Impact (2028+):</strong>
                            <ul style="margin: 15px 0 15px 20px;">
                                <li>Both face similar patent cliffs</li>
                                <li>Expected 40-60% price erosion</li>
                                <li>May actually increase utilization through improved access</li>
                                <li>Outcomes data will sustain relevance vs newer agents</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <script>
        function showTab(tabName) {
            // Hide all tab contents
            const tabContents = document.querySelectorAll('.tab-content');
            tabContents.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Show selected tab content
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }

        // Animate bars on first view
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const bars = entry.target.querySelectorAll('.bar');
                    bars.forEach((bar, index) => {
                        setTimeout(() => {
                            bar.style.animation = 'growBar 1s ease-out';
                        }, index * 100);
                    });
                }
            });
        });

        const chartContainers = document.querySelectorAll('.efficacy-bar-chart');
        chartContainers.forEach(container => {
            observer.observe(container);
        });

        // Add animation keyframe
        const style = document.createElement('style');
        style.textContent = `
            @keyframes growBar {
                from { transform: scaleY(0); }
                to { transform: scaleY(1); }
            }
        `;
        document.head.appendChild(style);

        // Add hover effects for timeline items
        document.querySelectorAll('.timeline-content').forEach(item => {
            item.addEventListener('mouseenter', function() {
                this.style.transform = 'scale(1.05)';
            });
            item.addEventListener('mouseleave', function() {
                this.style.transform = 'scale(1)';
            });
        });

        // Add smooth scrolling for internal navigation
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                e.preventDefault();
                document.querySelector(this.getAttribute('href')).scrollIntoView({
                    behavior: 'smooth'
                });
            });
        });
    </script>
</body>
</html>